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Abstract
Taxol triggers apoptosis in a variety of cancer cells, but it also upregulates cytoprotective proteins 
and/or pathways that compromise its therapeutic efficacy. In this report, we found that Taxol 
treatment resulted in caspase-8-dependent apoptosis in SKOV3 human ovarian cancer cells. 
Moreover, Taxol-induced apoptosis was associated with caspase-3 activation. Interestingly, Taxol 
treatment upregulated α-2,3-sialyltransferase (ST3Gal III) expression and forced expression of 
ST3Gal III attenuated Taxol-induced apoptosis. Furthermore, ST3Gal III overexpression inhibited 
Taxol-ttiggered caspase-8 activation, indicating that ST3Gal III upregulation produces cellular 
resistance to Taxol and hence reduces the efficacy of Taxol therapy.
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Introduction
The glycosylation of proteins is important for their biological activity, conformation, and 
stability. Sialic acids are terminal sugars on oligosaccharides that are attached to 
glycoproteins or lipid moieties; the transfer of sialic acids from GMP-sialic acid to an 
acceptor carbohydrate is catalyzed by sialyltransferases [1-5]. Sialic acids of cell surface 
glycoconjugates play a pivotal role in cellular structure and function. Sialyltransferases play 
a role in a variety of biological processes, including cell–cell communication, cell-matrix 
interaction, adhesion, and protein targeting [1, 6–8]. A large body of evidence indicates that 
tumor cells have different surface properties compared to their nonnal counterparts, and that 
these differences are partially due to aberrant glycosylation (altered sialo-glycoconjugates 
expressed on the plasma membrane) [1, 9, 10]. These altered surface glycosylations change 
the ability of cancer cells to invade and metastasize [11–14]. Altered expression of α-2,3-
sialyltransferase mRNA has been shown in ovarian cancer [15]. The most expressed 
sialyltransferase in breast tumors was ST3Gal III, which is involved in Sialyl-Lewis X 
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(SLX) synthesis, and its expression was positively correlated with tumor size and the 
number of axillary nodes involved [16]. High levels of ST3Gal III expression in human 
tumors are associated with poor prognosis and metastasis [12, 15, 17].
Taxol (paclitaxel) is one of the most active cancer chemotherapeutic agents known and is 
effective against several human malignancies, including ovarian, breast, and non-small cell 
lung cancer (NSCLC) [18–23]. Taxol promotes microtubule (MT) assembly, which 
produces a change in MT dynamics that disrupts the reorganization of the microtubule 
network required for mitosis and cell proliferation [24]. As a result, cells treated with Taxol 
are arrested in the G1 and G1/M phases of the cell cycle [25]. Other critical actions of Taxol 
include the induction of apoptosis and necrosis [26, 27]. However, Taxol can also upregulate 
cytoprotective pathways in cancer cells that compromise its therapeutic efficacy [28-31]. 
Therefore, targeted therapeutics against the Taxol-induced cytoprotective signals may offer 
a rational strategy to improve the anticancer efficacy of Taxol. In this report, we find that 
Taxol treatment results in upregulation of ST3Gal III expression in SKOV3 human ovarian 
cancer cells.
Moreover, forced ST3Gal JJI expression attenuated Taxol-induced apoptosis by inhibiting 
caspase-8 activity, indicating that ST3Gal III upregulation produces cellular resistance to 
Taxol and hence reduces the efficacy of Taxol therapy. Therefore, ST3Gal III could serve as 
a therapeutic target of Taxol therapy.
Materials and methods
Cell culture and Taxol treatment
The human SKOV3 cell line was purchased from American Type Culture Collection 
(ATCC, Rockville, MD). Cells were maintained in RPMI media (Mediatec Inc., Herndon, 
VA) supplemented with 10% fetal bovine serum (FBS) at 37°C in 5% CO2. Generally, 2 × 
105 cells/well were plated in six-well plate and incubated overnight. The next day, 100 nM 
Taxol dissolved in dimethylsulfoxide (DMSO) were added into the indicated wells, and an 
equal amount of DMSO was added into control wells. The final concentration of DMSO was 
less than 0.1%. After 48 h treatment, cells were collected for apoptosis analysis.
Identification of ST3Gal JJI in Taxol-treated cells
To identify potential cytoprotective signaling molecules upregulated in cancer cells by the 
toxic insult of Taxol, we conducted an unbiased proteomic analysis. Briefly, lysates of 
Taxol-treated versus untreated CCRF-HSB-2 leukemia cells were resolved on 2D-SDS-
PAGE gels, and protein spots were visualized by silver staining with a Silver Stain Plus kit 
(Bio-Rad, Hercules, CA). Taxol-upregulated protein species were identified, excised, and in-
gel digested with trypsin. Protein identification was performed by matrix-assisted laser 
desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (MS). One of these 
proteins was identified as ST3Gal III, an enzyme important in several cancer types including 
ovarian cancer [15–17]. To confirm our MS results and to establish whether ST3Gal III is 
involved in Taxol-induced apoptosis, we treated SKOV3 ovarian cancer cells with Taxol 
and confirmed that Taxol increases expression of ST3Gal III.
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Cloning of ST3GAL III
To clone the full-length ST3Gal III-B1 gene, we used the ST3Gal III-B1-specific sense 
primer 5′-GCGATGGGAC TCTTGGTATTTG-3′ and the ST3Gal III-B1-specific anti-sense 
primer 5′-GATGCCACTGCTTAGATCAGTG-3′ to amplify the coding region using the 
template provided by Grahn et al. [32]. The full-length ST3Gal JJI DNA fragment was 
purified and subcloned into the pEF6/V5-His TOPO expression vector (lnvitrogen Corp., 
Carlsbad, CA) to produce ST3Gal III-EF6. The human ovarian cell line SKOV3 was 
transfected with ST3Gal III-EF6 using Fu-GENE 6 transfection reagent according to the 
manufacturer’s instructions (Roche Diagnostics, Indianapolis, IN), and stable clones were 
obtained by adding 10 μg/ml Blastacidin (Invitrogen) to the growth media. Cells transfected 
with ST3Gal III-EF6 or the empty plasmid pEF/V5-His were grown in a 6-well plate (5–100 
cells/well), and after 2 weeks of growth, two cell clones from each sample were isolated and 
expanded for further studies.
RNA isolation and RT-PCR
Total RNA from Taxol-treated and untreated cells was isolated using the RNeasy Mini Kit 
(Qiagen, Valencia, CA) as described by the manufacturer. Two micrograms of total RNA 
was used in reverse transcription reactions with M-MLV reverse transcriptase and oligo (dT) 
15 primer (Promega, Madison, WI) as described by the manufacturer. Four microliters of the 
resulting total cDNA were then used as the template in PCR to measure the mRNA level of 
interest using the designed primers: (forward, 5′-GCGAT GGGACTCTTGGTATTTG-3′; 
reverse, 5′-GATGCCACT GCTTAGATCAGTG-3′). The reactions were performed for 
denaturation at 95°C for 55 s, annealing at 55°C for 55 s, and extension at 72°C for 2 min 
for a total of 30 cycles. β-actin mRNA levels were used as internal controls. The amplified 
fragments (1128 bp) were separated on 1.5% agarose gels and visualized by ethidium 
bromide staining.
Annexin V binding assay for detecting apoptotic cells
Following treatment as stated above, the cells (5 × 105 cells/treatment) were used to 
dete1mine the translocation of phosphatidylserine to the outer surface of the plasma 
membrane during apoptosis using annexin V binding assay. For this assay, the cells were 
incubated with Taxol as described above, harvested, and stained with fluorescein 
isothiocyanate-labeled annexin V (BO Biosciences, San Jose, CA) and propidium iodide 
according to the manufacturer’s protocol. Apoptosis and necrosis were analyzed by quadrant 
statistics on the propidium iodide (PI)-negative, Ruorescein-positive cells, and PI-positive 
cells, respectively.
Western blot analysis
In this study, the following primary antibodies were used: anti-caspase-8, anti-caspase-3 
(Cell Signaling Technology, Danvers, MA), anti-V5 antibody (lnvitrogen Corp., Carlsbad, 
CA), anti-β-actin clone AC-74 (Sigma-Aldrich, St. Louis, MO), and the human ST3Gal-III 
antibody (gift from Dr. Göran Larson, Institute of Laboratory Medicine, Department of 
Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, SE 413 45 
Götcborg, Sweden). Protein concentrations were determined by using the BCNCu2SO4 
Huang et al. Page 3









protein (Sigma-Aldrich) assay as described by the manufacturer. For Western blot analysis, 
50 μg protein/lane were separated by 12% SDS-PAGE, blotted onto a PVDF Immobilon 
membrane, and then the protein levels were detected using peroxidase-conjugated secondary 
antibodies as described by the manufacturer. The primary antibody was used al a 
concentration of 1:2000 (v/v). The membranes were then exposed to Kodak X-Omat film for 
various times. The mouse monoclonal anti-β-actin (clone AC-74) was purchased from 
Sigma-Aldrich (St. Louis, MO) and used al 1:5000 (v/v).
siRNA preparation and transfection
The ON-TARGET plus SMARTpool caspase-8 siRNA was synthesized by Dharmacon and 
siCONTROL non-targeting siRNA (catalog number D-001210-03) was purchased from 
Dharmacon Research, Inc. (Lafayette, CO). SKOV3 cells were seeded at a density of 2 × 
105 cells/ml in antibiotic-free medium I day prior to transfection. For transfection, 100 nM 
of siRNA were mixed with DharmaFECT 1 transfection reagent (Dharmacon) according to 
the manufacturer’s instructions. The cells were incubated with the siRNA-DharmaFECT 1 
complexes for 48 h and 100 nM of Taxol were subsequently added.
Results
ST3Gal III Is induced during Taxol-induced apoptosis
We have found that Taxol at 100–500 nM induces robust apoptosis in cell lines from 
differenl. types of cancer. As shown in Fig. 1a and b, Taxol induced apoptosis in 35% of the 
SKOV3 cells, and immunoblot blot analysis of cell lysates showed that while SKOV3 cells 
express little ST3Gal III protein, its level of expression was significantly increased after 
Taxol treatment. Next, we determined whether the Taxol-mediated induction of ST3Gal III 
expression occurred at the transcriptional or post-transcriptional level. RT-PCR analysis 
showed that Taxol treatment did not affect the ST3Gal III transcript level, indicating that 
Taxol increases ST3Gal III by a post-transcriptional mechanism (Fig. 1e). Similar results 
were obtained when CCRF-HSB-2 leukemia and MCF-7 breast cancer cells were treated 
with Taxol (data not shown). These results reveal that Taxol induces the expression of 
ST3Gal III by a post-transcriptional mechanism in SKOV3 cells.
Expression of ST3Gal III decreases Taxol-induced apoptosis in SKOV3 cells
To determine the role of ST3Gal III in Taxol-induced apoptosis, we constmcted a ST3Gal 
III-EF6 plasmid and transfected SKOV3 cells. Stable SKOV3 transfected populations 
harboring the ST3Gal III-EF6 plasmid contained elevated levels of ST3Gal III as 
determined by immunoblot analysis (Fig. 2a). Treatment of SKOV3 cells with 100 nM 
Taxol for 48 h induced apoptosis in 38% of the cells, as compared to 22% in transfectants 
expressing ST3Gal III (Fig. 2b). These results show that the overexpression of ST3Gal III 
reduces Taxol-induced apoptosis of SKOV3 cells (P < 0.05). To prove that the antiapoplotic 
effect of ST3Gal III on Taxol-triggered apoptosis is not due to clonal differences between 
the blasticidin-resistant cell clones, we compared two ST3Gal III expressing cell clones with 
two cell clones containing the empty expression vector. Western blot analysis showed 
overexpression of ST3Gal III in both the cell clones transfected with the ST3Gal III 
expression vector (Fig. 3a). The results shown in Fig. 3b clearly show that Taxol-induced 
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apoptosis was significantly reduced in both of the cell clones overexpressing ST3Gal III 
compared with the cell clones containing the empty plasmid (P < 0.05).
Taxol triggers caspase-8-mediated apoptosis in SKOV3 cells
We next examined the role of caspase-8 in Taxol-induced apoptosis, since it is a central 
caspase in the death receptor and mitochondrial apoptotic signaling pathways. SKOV3 cells 
were treated with Taxol and caspase-8 levels were analyzed by immunoblotting. As shown 
in Fig. 4a, Taxol induced the processing of caspase-8 to its active pl8 sub-unit, revealing that 
caspase-8 is involved in mediating Taxol’s death signals. To directly assess the function of 
caspase-8 in Taxol-triggered apoptosis in SKOV3 cells, we silenced the caspase-8 gene 
using a caspase-8-specific siRNA (Fig. 4b). Moreover, the knockdown of caspase-8 
decreased Taxol-induced apoptosis from 35% to 25% in SKOV3 cells (Fig. 4c). These data 
reveal that Taxol induces apoptosis in SKOV3 cells by a caspase-8-mediated mechanism (P 
< 0.05).
Overexpression of ST3Gal III inhibits Taxol-induced activation of caspase-8 in SKOV3 cells
While the results shown in Fig. 5 demonstrate that Taxol induced processing of pro-
caspase-8 to its active form in the two cell clones expressing the empty expression vector, 
the ectopic expression of ST3Gal III inhibited this process, and significantly less active 
caspase-8 was formed in the two cell clones expressing ST3Gal III. Moreover, Taxolinduced 
apoptosis was associated with significantly reduced caspase-8, -9, and -3 activation in the 
two cell clones expressing ST3Gal III compared to the cell clones with the empty vector. 
These data clearly show that ST3Gal III functions as an endogenous caspase-8 inhibitor in 
SKOV3 cells, and decreasing ST3Gal III expression may be a useful strategy to sensitize 
ovarian cancers to Taxol.
Discussion
In this study, for the first time we showed that Taxol triggers caspase-8-mediated apoptosis 
in SKOV3 ovarian cancer cells. A previous study showed that treatment of SKOV3 cells 
with Taxol did not lead to caspase-3 and -9 activation [27]. Moreover, another report 
indicated that Taxol induces caspase-independent apoptosis [33]. However, our results show 
that Taxol-induced apoptosis is associated with caspase-8, -9, and -3 activation in these 
cells. We previously demonstrated that low Taxol concentrations triggered caspase-8- and 
caspase-10-dependent apoptosis in the CCRF-HSB-2 human lymphoblastic leukemia cell 
line, and induced downregulation of the FLICE inhibitory protein variants, c-FLIP8 and c-
FLIPc [34]. Our results also corroborate previous reports showing that incubation with 
Taxol leads to caspase-8 activation in the human colon cancer cell line HT29-D4 [35, 36] 
and in the lung adenocarcinoma LC-2-AD cell line [37]. Furthermore, it was reported that 
during Taxol treatment in BJAB Burkitt-like lymphoma cells, both caspases-3 and -8 are 
part of a mitochondrial feedback amplification loop of apoptosis [38]. We [39] and others 
[40] have shown that overexpression of a dominant negative FADD (dnFADD) is unable to 
recruit caspase-8/10, and this protects against Taxol-induced apoptosis in Jurkat cells and 
CCRF-HSB-2 human lymphoblastic leukemia cells [39, 40]; however; other studies revealed 
that FADD is not involved in this process in B-lymphoma cells [38, 41]. Several sludies 
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have demonstrated caspase-9 activation during Taxol-induced apoptosis [38, 42, 43]; 
however, we [39] and others could not detect cleavage of caspase-9 [27]. It appears that the 
effects of Taxol on caspase-9 activation are cell type specific. For instance, Taxol-induced 
cleavage of caspase-9 was shown in the HL-60 human leukemia cell line [44]. Therefore, 
the data collectively indicate that Taxol uses varying apoptosis signaling pathways in 
different cell types.
Epithelial ovarian cancer is the leading cause of death in women with gynecological tumors. 
Usually, after an initial high response rate, the patient relapses and the tumor acquires 
resistance to chemotherapy. Defects in apoptotic signaling pathways contribute to drug 
resistance in ovarian cancer [45, 46]. In the search to identify novel cytoprotective signaling 
molecules, we found for the first time that ST3Gal III expression is upregulated in Taxol-
treated SKOV3 cells. Similar results were obtained in MCF-7 breast cancer and CCRF-
HSB-2 human lymphoblastic leukemia cell lines (data not shown). Furthermore, our data 
revealed that increased expression of ST3Gal III serves a cytoprotective function and 
prevents Taxol-induced apoptosis by inhibiting caspase-8 activation.
ST3GALIII is a member of sialytransferases family which is mostly resident in the Golgi 
apparatus. Sialytransferases specifically catalyze the transfer of sialic acid from CMP-sialic 
acid to oligosaccharides. Each sialytransferase is unique for a pa1ticular sugar substrate. 
Sialytransferases add sialic acid to the terminal portions of sialylated glycolipids or to the N-
or O-linked sugar chains of glycoproteins. These sialytransferases are distinguished from 
each other based on the different substrate structures and the different sugar linkages they 
form [47]. Some catalyze an a-2,3 linkage to add sialic acid to a galactose residue in the 
glycoprotein; others catalyze an α-2,6 linkage adding sialic acid to galactose residues [48, 
49]. ST3GAL III is normally found in the Golgi apparatus, but can be proteolytically 
processed to a soluble form. Human ST3GAL III (Galβ1-3(4)GlcNAc α-2,3-
sialytransferase) preferentially acts on the chain Galβ-3GlcNAc, and is therefore involved in 
synthesizing the sialyl-Lewis epitope in vivo [50].
To our knowledge, this is the first report describing the role of ST3Gal III as an anti-
apoptotic protein. It is tempting to speculate that ST3Gal III may alter the sialylation of 
glycoproteins involved in apoptosis and/or interact with proteins in the death-inducing 
apoptosis signaling complex.
Identification of the critical apoptosis regulatory molecular targets of Taxol in cancer cells 
may lead to improved cancer therapy regimens that utilize a lower dose of Taxol, thereby 
limiting systemic toxicities. Moreover, identifying novel cytoprotective molecules such as 
ST3Gal III capable of preventing Taxol-triggered apoptosis validates these molecules as 
rational targets to sensitize cancers to Taxol’s death signals. Investigating these targets and 
their roles in Taxol-induced apoptosis will also provide novel information on the specific 
signaling pathways involved in this process, which could be useful for discovering drugs 
with greater selectivity and efficacy. The molecular mechanism of upregulating ST3Gal III 
by Taxol and how it decreases caspase-8 activation are being pursued in our laboratory. 
Whether Taxol-triggered upregulation of ST3Gal III results in increased sialylation of 
specific target proteins involved in preventing apoptosis in cancer cells remains to be found. 
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However, strategies to silence the expression of ST3Gal III and/or inhibit its activity by 
small molecule inhibitors are likely to render cancer cells more sensitive to Taxol-induced 
apoptosis.
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Taxol-induced apoptosis and ST3Gal III expression in SKOV3 cells. a Cells were treated 
with 100 nM taxol for 48 h, harvested, and apoptosis was determined by FACS analysis as 
described in section “Matrial and Methods”. Compensation was executed for each 
experiment using untreated cells and cells stained only with Annexin V or propidium iodide, 
respectively. Error bars show standard deviation from triplicate measurements. * p < 0.05. b 
Immunoblot analysis of ST3Gal III and β-actin in cell lysates following the treatment with 
100 nM Taxol. c Total RNA from SKOV3 cells was extracted and the levels of ST3Gal III 
mRNA were measured by RT-PCR. β-actin was used as an internal control in the RT-PCR 
reactions
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Overexpression of ST3Gal III inhibits the Taxol-induced apoptosis of SKOV3 cells. a Total 
RNA was isolated from SKOV3 cells or the SKOV3 stable cell line transfected with the 
ST3GAL III gene, and the expression of ST3Gal III was measured by RT-PCR. b Cell 
lysates from SKOV3 and SKOV3 cells stably transfected with the ST3Gal III gene were 
collected. Immunoblot analysis of ST3Gal III expression was conducted. c SKOV3 and 
SKOV3/ST3Gal III cells were treated with 100 nM Taxol for 48 h, harvested, and apoptosis 
was determined by FACS analysis as described in the section “Material and Methods”. 
Compensation was executed for each experiment using untreated cells and cells stained only 
with annexin V or propidium iodide, respectively. Error bars show standard deviation from 
triplicate measurements. * P < 0.05
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ST3Gal III attenuates the Taxol-induced apoptosis. a Western biot analysis of ST3Gal III 
expression in two SKOV3 cell colonies using V5 antibody. Two SKOV3 cell clones 
expressing the empty vector (E1 and E2) and two cell clones expressing ST3Gal III 
transfectants (ST3Ga1 III a and ST3Gal III b) were treated with 100 nM Taxol for 48 h, 
respectively, harvested, and apoptosis was determined as described in the section “Material 
and Methods”. Compensation was executed for each experiment using untreated cells and 
cells stained only with Annexin V or propidium iodide, respectively. Error bars show 
standard deviation fro1n triplicate measurements. * P < 0.05
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Taxol triggers caspase-8 mediated apoptosis in SKOV3 cells. a Cells were treated with 100 
nM Taxol for 48 h, harvested, and immunoblot analysis of caspase-8 and β-actin was 
conducted. b Immunoblot analysis of caspase-8 and β-actin in cell lysates following 
treatment with 100 nM of non-targeting siRNA (CS) or caspase-8-specific siRNA (CS) with 
or without Taxol for 48 h. c Cells were transfected with 100 nM non-targeting siRNA (CS) 
or caspase-8-specific siRNA (CS) for 48 h, and treated with or without 100 nM Taxol at the 
same time, harvested, and apoptosis was detennined by FACS analysis as described in the 
section “Material and Methods”. Error bars show standard deviation from triplicate 
measurements. * P < 0.05. Immunoblot analysis of caspase-8 was conducted
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ST3Gal III inhibits Taxol-induced activation of caspases-8, -9, and -3. Two SKOV3 cell 
clones with the empty vector and two cell clones expressing ST3Gal-III transfectants were 
treated with 100 nM Taxol for 48 h, respectively, harvested, and caspases-8, -9, and -3 were 
detected by Western blot analysis as described in the section “Material and Methods”. Note 
that forced expression of ST3Gal III attenuates Taxol-induced apoptosis and caspase-8, -9, 
and -3 activation
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